Zacks Investment Research · 11 Aug 2026neutral
Zacks Investment Research highlighted VNDA among four psoriasis drug stocks to watch during Psoriasis Awareness Month 2026, noting the company offers psoriasis opportunities spanning approved therapies, late-stage candidates, and earlier-stage programs.
Why it matters — The mention underscores that VNDA is one of a select group of companies with psoriasis-related drug assets across multiple stages of development, which may draw investor attention during Psoriasis Awareness Month.
Seeking Alpha · 6 Aug 2026neutral
Vanda Pharmaceuticals held its Q2 2026 earnings call, and Seeking Alpha published a transcript of the event covering the company's quarterly results and management commentary.
Why it matters — A VNDA watcher would care because the earnings call transcript provides direct insight into the company's latest quarterly financial performance and management's outlook.
MarketBeat · 6 Aug 2026neutral
Vanda Pharmaceuticals reported second-quarter 2026 revenue of $50.5 million, down 4% year over year, as growth in Fanapt and PONVORY was offset by lower HETLIOZ sales due to generic competition and shipment timing. The company reaffirmed its full-year revenue outlook and said operating expenses are expected to begin declining late this year, with larger reductions anticipated in 2027.
Why it matters — VNDA watchers would care because the results signal a modest revenue decline, ongoing generic pressure on HETLIOZ offset by Fanapt and PONVORY growth, and a planned path toward lower operating expenses through 2027.
Zacks Investment Research · 5 Aug 2026negative
Vanda Pharmaceuticals reported a second-quarter loss of $1.04 per share, which came in wider than the Zacks Consensus Estimate of a $0.51 loss and exceeded the $0.46-per-share loss posted a year ago. The company also lagged revenue estimates for the quarter.
Why it matters — For VNDA watchers, the wider-than-expected quarterly loss and revenue shortfall signal weaker-than-anticipated operating results for the period.
PRNewsWire · 5 Aug 2026positive
Vanda Pharmaceuticals reported second-quarter 2026 financial results, with Fanapt net product sales up 23% to $36.0 million and total prescriptions up 31%. The company guided full-year 2026 total revenue to $240-$290 million, held $170.0 million in cash expected to fund operations through at least the end of 2027, and noted that BYSANTI received FDA approval, NEREUS became commercially available, the Quimilza BLA is under FDA review with a December 12, 2026 PDUFA date, and results for three Phase III trials are expected by year-end.
Why it matters — VNDA watchers would care because the results show continued Fanapt growth and a pipeline advancing with an FDA-approved product launching, a BLA under review, and multiple Phase III readouts expected by the end of 2026.
